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A bs tr ac t
Background
Women with cystic fibrosis are at increased risk for mucoid conversion of Pseudomonas 
aeruginosa, which contributes to a sexual dichotomy in disease severity.
Methods
We evaluated the effects of estradiol and its metabolite estriol on P. aeruginosa in vitro 
and in vivo and determined the effect of estradiol on disease exacerbations in women 
with cystic fibrosis.
Results
Estradiol and estriol induced alginate production in P. aeruginosa strain 01 and in 
clinical isolates obtained from patients with and those without cystic fibrosis. After 
prolonged exposure to estradiol, P. aeruginosa adopted early mucoid morphology, 
whereas short-term exposure inhibited bacterial catalase activity and increased lev-
els of hydrogen peroxide, which is potentially damaging to DNA. Consequently, a 
frameshift mutation was identified in mucA, a key regulator of alginate biosynthesis 
in P. aeruginosa. In vivo levels of estradiol correlated with infective exacerbations in 
women with cystic fibrosis, with the majority occurring during the follicular phase 
(P<0.05). A review of the Cystic Fibrosis Registry of Ireland revealed that the use of 
oral contraceptives was associated with a decreased need for antibiotics. Predomi-
nantly nonmucoid P. aeruginosa was isolated from sputum during exacerbations in the 
luteal phase (low estradiol). Increased proportions of mucoid bacteria were isolated 
during exacerbations occurring in the follicular phase (high estradiol), with a vari-
able P. aeruginosa phenotype evident in vivo during the course of the menstrual cycle 
corresponding to fluctuating estradiol levels.
Conclusions
Estradiol and estriol induced mucoid conversion of P. aeruginosa in women with cystic 
fibrosis through a mutation of mucA in vitro and were associated with selectivity for 
mucoid isolation, increased exacerbations, and mucoid conversion in vivo. (Funded by 
the Molecular Medicine Ireland Clinician–Scientist Fellowship Programme.)
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P seudomonas aeruginosa is a gram-nega-tive opportunistic pathogen associated with cystic fibrosis,1 a multisystem genetic dis-
ease characterized by defects in the cystic fibro-
sis transmembrane conductance regulator (CFTR) 
protein, which results in recurrent infective exac-
erbations. Median overall survival among pa-
tients with cystic fibrosis in the United States is 
39 years, although a sexual dichotomy persists in 
disease severity,2-4 with women having a survival 
disadvantage and poorer lung function.5-7
The Republic of Ireland has the highest inci-
dence and carrier rate of cystic fibrosis worldwide8 
and a survival disadvantage for women.9 Patients 
with cystic fibrosis become colonized and infected 
with nonmucoid P. aeruginosa; these strains convert 
to mucoid strains, on average, at a younger age 
in women than in men.3,10,11 In an attempt to 
explain these observations, we and others have 
investigated the effect of the female sex hormone 
estradiol on airway biology. Women with cystic 
fibrosis appear to be at greater risk for exacerba-
tions during periods of high circulating levels of 
estradiol, when airway-surface liquid is dimin-
ished and antimicrobial peptides are scarce and 
there is a blunted inflammatory response to micro-
bial agonists.12-14 However, these observations 
have not been confirmed in vivo. In addition, the 
role of estradiol-derived metabolites in cystic fibro-
sis remains largely unknown, with limited data 
linking estradiol with pseudomonas infection.14
The persistence of P. aeruginosa in cystic fibrosis 
has been attributed to hypermutability, drug re-
sistance, loss of virulence, reduced bacterial kill-
ing, and defective CFTR.14-16 Antibiotics delay but 
do not prevent mucoid conversion. Of equal sig-
nificance is the capacity of P. aeruginosa to form 
biofilms and convert to mucoidy in vivo.
Alginate, the predominant polysaccharide pro-
duced by P. aeruginosa, defines its mucoid conver-
sion; it is implicated in pathogenicity and can 
induce parenchymal damage.17 Nonmucoid 
P. aeruginosa can be induced to release alginate 
under conditions characteristic of the lung milieu 
in patients with cystic fibrosis.18,19 The production 
of biofilms is influenced by alginate, but the 
presence of the polysaccharide is not essential for 
biofilm formation.20,21 The principal gene control-
ling alginate biosynthesis, mucA, encodes an anti-
sigma factor that normally prevents algT from 
inducing expression of algD.22,23 Alginate pro-
duction and mucoid conversion are attributed to 
loss-of-function mutations in mucA, resulting in 
derepression of algT and concomitant induction 
of algD.
The sex-specific effects of P. aeruginosa in 
women with cystic fibrosis may be attributed to 
estradiol.12-14 Here we evaluate the effect of es-
tradiol and its metabolite estriol on laboratory 
and clinical isolates of P. aeruginosa and prospec-
tively assess the effect of estradiol on infective 
exacerbations in women with cystic fibrosis.
Me thods
Laboratory Testing
Full details with respect to the P. aeruginosa strain 
01 (PA01),24 clinical isolates, culture conditions, 
bronchoscopy, cell culture, quantitative reverse-
transcriptase–polymerase-chain-reaction assay, 
DNA sequencing of the P. aeruginosa phenotype,25 
and assays of catalase, hydrogen peroxide, algi-
nate,26 and estradiol are provided in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
Patients
From July 2008 through July 2010, we recruited all 
female patients with cystic fibrosis who presented 
to Beaumont Hospital in Dublin (44) with a total of 
139 infective exacerbations, as defined by the crite-
ria of Fuchs et al.27 (Table S3 in the Supplementary 
Appendix). All patients provided written informed 
consent, and appropriate approval was obtained 
from the hospital’s institutional review board.
Statistical Analysis
Data were analyzed by descriptive, exploratory 
(comparative), and modeling approaches and 
methods, including a technique of generation of 
random numbers. All results are expressed as ab-
solute numbers and percentages, as well as means 
±SD or means ±SE. We used the chi-square test 
or Fisher’s exact test to compare categorical data 
distributions and Kolmogorov–Smirnov or Shapiro-
Wilk methods, as appropriate, to test continuous 
data for normality of distribution. We used para-
metric methods and tests (e.g., Student’s t-test) to 
analyze normally distributed data and two-group 
nonparametric Wilcoxon signed-rank and Mann–
Whitney U tests to analyze data deviating from a 
normal distribution. We used the nonparametric 
Kruskal–Wallis test for the comparison of more 
than two independent groups. To describe exist-
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ing linear trends over years, we calculated the 
coefficients of the models (intercepts, slopes, and 
squares of the correlation coefficient [R2]). Sta-
tistical analyses were performed with SPSS soft-
ware, version 18 (IBM); GraphPad Prism, version 
4.0 (GraphPad Software); and modeling tools as 
integrated in Microsoft Office Excel 2007, version 
SP2 MSO (Microsoft). All reported P values are 
two-sided, and a P value of 0.05 was considered 
to indicate statistical significance, unless stated 
otherwise.
R esult s
Effect of Estrogen on Alginate Production
At baseline, PA01 is nonmucoid. However, it can be 
induced under appropriate conditions to produce 
alginate.24,28 We examined the effect of estradiol 
and estriol on alginate production in PA01 and in 
clinical isolates of P. aeruginosa obtained from pa-
tients with and those without cystic fibrosis (Fig. 
1A). Testosterone (an estradiol precursor) and eth-
anol were used as controls. After 3 days of expo-
sure, 10 nM of estradiol induced more alginate pro-
duction by PA01 (33.5 μg per milliliter) than did 
the same amounts of testosterone (9.6 μg per 
milliliter) and ethanol (9.5 μg per milliliter) (P<0.05 
for both comparisons). The increase in alginate 
production was time-dependent, with increased 
levels (92.2 μg per milliliter) produced after 4 weeks 
in continued subculture with estradiol (P<0.01 for 
both comparisons). Testosterone had no effect on 
alginate production at 4 weeks. After 3 days, estriol 
induced significantly more alginate production 
(143.1 μg per milliliter) than an equal amount of 
estradiol (P<0.005). Nonmucoid clinical isolates of 
P. aeruginosa similarly produced more alginate af-
ter treatment with 10 nM of estradiol or estriol 
for 3 days (P<0.005). Estradiol up-regulates the 
expression of algD, algT, and mucA in PA01 (Fig. S1 
in the Supplementary Appendix), and estriol was 
detected in samples of estradiol-treated, immor-
talized bronchial epithelial cells obtained from 
patients with and those without cystic fibrosis and 
in bronchoalveolar-lavage fluid from patients with 
cystic fibrosis (Fig. S2 and S3 in the Supplemen-
tary Appendix).
Mucoid Conversion of P. aeruginosa
Blue agar plates were used to detect mucoid colo-
nies.25 After daily subculture for 3 days in fresh 
broth containing estradiol, testosterone, or ethanol 
with daily replenishment, no differences in mor-
phology were observed. However, after 4 weeks, 
early mucoid colony formation was noted in the 
estradiol-treated cultures (Fig. 1B). More mucoid 
colonies were detected in the estradiol-treated 
cultures (5.5×108 colony-forming units [CFU] per 
milliliter for mucoid colonies vs. 2.9×109 CFU per 
milliliter for nonmucoid colonies), than in ethanol-
treated cultures (3.3×108 CFU per milliliter for 
mucoid colonies vs. 5.0×109 CFU per milliliter for 
nonmucoid colonies) or testosterone-treated cul-
A
lg
in
at
e 
(µ
g/
m
l)
250
150
200
100
50
0
PA01 (3 days) PA01 (4 wk) CF (3 days) Non-CF (3 days)
B Mucoid Conversion
A Alginate Production
Ethanol Estradiol EstriolTestosterone
Vehicle Control Estradiol Testosterone
*
*
* †
*
*
* *
Figure 1. Alginate Production and Mucoid Conversion in Pseudomonas 
 aeruginosa Induced by Estradiol and Estriol.
In Panel A, P. aeruginosa strain 01 (PA01) or P. aeruginosa clinical isolates 
from patients with and those without cystic fibrosis (CF) were treated for 
either 3 days or 4 weeks with daily subculture in fresh broth containing etha-
nol, testosterone, estradiol, or estriol (10 nM for each subculture). Alginate 
was measured with the use of the uronic acid–carbazole reaction method 
in three experiments. Data are expressed as means, with T bars indicating 
the standard deviation. The asterisk indicates P<0.05 for the comparison 
with ethanol or testosterone; the dagger indicates P<0.01 for the compari-
son between 3 days and 4 weeks of treatment with estradiol in PA01. Algi-
nate levels were not determined in PA01 at 4 weeks in response to estriol or 
in CF and non-CF isolates at 3 days in response to testosterone. In Panel B, 
PA01 was plated onto blue agar after daily subculture for 4 weeks in fresh 
broth cultures containing ethanol (vehicle control), estradiol, or testosterone 
(10 nM of each substance). Representative culture plates are shown for three 
experiments. Mucoid colonies are indicated by arrows.
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tures (3.1×108 CFU per milliliter for mucoid colo-
nies vs. 4.53×109 CFU per milliliter for nonmucoid 
colonies), equating to 15.9%, 6.2%, and 6.4% 
mucoid colonies, respectively.
Genetic Mutations and Mucoid Conversion
Conversion to mucoidy within the lungs of pa-
tients with cystic fibrosis results from spontane-
ous mutations in mucA, which was sequenced in 
both mucoid and nonmucoid colonies grown in 
estradiol and ethanol, respectively. In 80% of mu-
coid colonies with exposure to estradiol, a deletion 
of the nucleotide adenine at position 60 of mucA 
occurred, resulting in a frameshift mutation of 
glutamic acid (E) to aspartic acid (D) at residue 
20 of the MucA protein and the introduction of a 
premature stop codon (Fig. S4 in the Supplemen-
tary Appendix). One mechanism by which this 
occurs involves estradiol-induced inhibition of 
catalase activity and increased production of hy-
drogen peroxide in P. aeruginosa (Fig. S5 in the 
Supplementary Appendix).
Estradiol Levels and Infective Exacerbations
To assess whether fluctuations in estradiol levels 
during the menstrual cycle are associated with 
infective exacerbations, we performed a 24-month 
prospective clinical study in which we assessed 
139 exacerbations in 44 women with cystic fibro-
sis. We excluded patients who reported having 
irregular menstrual cycles or the use of oral con-
traceptives. We plotted 72 exacerbations related 
to a regular menstrual-cycle pattern in 23 women 
according to the stage of the cycle when the ex-
acerbation occurred. A serum estradiol curve was 
prospectively generated from data obtained from 
6 women with cystic fibrosis who had a regular 
menstrual cycle. Exacerbations closely mirrored in 
vivo estradiol levels. Significant increases in the 
number of exacerbations occurred during the fol-
licular phase, when estradiol levels peak (P<0.05) 
(Fig. 2A, and Table S3 in the Supplementary Ap-
pendix).
To validate the relationship between elevated 
estradiol levels and the number of infective exac-
erbations, we assessed serum from 172 patients 
with cystic fibrosis during a 36-month period (Fig. 
2B, and Table S4 in the Supplementary Appen-
dix). The mean serum estradiol level was signifi-
cantly higher in women with exacerbations than 
in those with stable disease (777 pmol per liter 
vs. 303 pmol per liter, P<0.008). This pattern was 
absent in women receiving oral contraceptives 
and in men. The exacerbation rate per year was 
significantly lower in women receiving oral con-
traceptives than in other groups (Fig. S6 in the 
Supplementary Appendix).
Irish Registry Data
Next we analyzed data from the Cystic Fibrosis 
Registry of Ireland during years when the rate of 
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Figure 2. Exacerbations and Estradiol Levels in Women with Cystic Fibrosis.
Panel A shows the number of infective exacerbations according to the time 
of the menstrual cycle, as recorded for 44 women with cystic fibrosis and 
plotted against circulating estradiol levels (as measured in 6 women with 
cystic fibrosis). Shown are means and the range of values. The asterisk in-
dicates P<0.05 for the comparison between the proliferative phase of the 
menstrual cycle (the highest estradiol level) and the menstrual, ovulatory, or 
secretory phase. Panel B shows serum estradiol levels for 172 patients with 
cystic fibrosis (CF) classified according to sex and use of oral contracep-
tives (OC). The double asterisks indicate P<0.01, and the triple asterisks in-
dicate P<0.001.
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ascertainment (i.e., the proportion of registered 
patients vs. the census population of persons with 
cystic fibrosis) was more than 55% (2006 through 
2009) among women 18 years of age or older, ac-
cording to their use of oral contraceptives (Table 
S8 in the Supplementary Appendix). Of the 239 
patients whose data were analyzed, 15.1% used oral 
contraceptives, although the type of oral contra-
ceptive was not recorded. For standardization and 
because definitions of exacerbations vary among 
centers, we assessed the mean number of antibi-
otic courses (either oral or intravenous) required 
for the treatment of clinical deterioration and its 
relationship to the use of oral contraceptives. In 
order to compare the 36 women receiving oral 
contraceptives with those not receiving oral con-
traceptives in an approximate ratio of 1:1, we se-
lected a random sample of 41 control women from 
the remaining 203 women in the registry (approx-
imately 20%). We found a decreasing tendency to 
require antibiotics in women receiving oral con-
traceptives, as compared with those not receiving 
oral contraceptives (Fig. 3). These differences were 
most significant where registry ascertainment 
was highest (Table S8 in the Supplementary Ap-
pendix). There was a significant reduction in the 
mean number of antibiotic courses required dur-
ing times when individual women were receiving 
oral contraceptives, as compared with times they 
were not receiving oral contraceptives (Fig. S7 in 
the Supplementary Appendix).
Sex Differences in Colonization and Mucoid 
Conversion
In patients with stable cystic fibrosis who were 
colonized with P. aeruginosa, mucoid P. aeruginosa 
was isolated at twice the frequency in women as 
in men as a proportion of total culture counts 
(26.2% mucoid cultures in 6 women vs. 10.0% in 
4 men) (Table S6 in the Supplementary Appen-
dix). To assess rates of P. aeruginosa colonization 
and mucoid conversion, we explored all data from 
the Irish registry up to December 31, 2010 (in-
volving 455 women and 554 men) (Table S9 in the 
Supplementary Appendix). Chronic colonization 
was defined as isolation of P. aeruginosa from at 
least two sputum samples obtained 6 months apart 
(in ≥50% of samples) in consecutive years, the 
first of which was recorded as the year of acquisi-
tion. In this analysis, 375 of 1009 patients (37.2%) 
were colonized by P. aeruginosa, with a mean (±SD) 
age of acquisition of 20.8±9.0 years, as defined by 
the modified Leeds criteria.29 The female patients 
had significantly higher colonization rates (abso-
lute difference, 11.9 percentage points; P<0.001) 
and acquired it 2.3 years earlier (19.7 vs. 22.0 years, 
P = 0.01) (Table S9 in the Supplementary Appendix). 
P. aeruginosa converted to mucoidy in significantly 
more female patients (Fig. S8 in the Supplemen-
tary Appendix), and the conversion occurred 1.8 
years earlier in women than in men (Table S9 in 
the Supplementary Appendix).
P. aeruginosa Phenotype According to 
Menstrual Cycle
We recorded the predominant P. aeruginosa pheno-
type in sputum samples obtained from patients 
in the prospective study. Of the 72 exacerbations in 
23 patients who were included in the final analysis, 
P. aeruginosa was not isolated from 4 patients in 
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Figure 3. Effect of Oral Contraceptives on the Number of Courses 
of Antibiotics Required per Year in Women with Cystic Fibrosis.
Available data from the Cystic Fibrosis Registry of Ireland for 239 women 
(≥18 years of age) were obtained for the years 2001 through 2010, but only 
years when registry ascertainment was more than 55% (2006–2009) are 
shown. The mean numbers of courses of antibiotics (oral or intravenous) 
that were received for clinical deterioration, as determined by the local at-
tending physician, are shown for 36 women receiving oral contraceptives 
(OC), as compared with a random sample of 41 women not receiving oral 
contraceptives (approximately 20% of the sample), for the respective time 
periods. Opposing trends were detected between the two groups. The 
model equations present the coefficients of linear regression: intercept a, 
slope b, and the square of the correlation coefficient (R2) for the decreasing 
tendency of women receiving oral contraceptives to require antibiotics 
 (orange line) versus the increasing tendency of women not receiving oral  
contraceptives to require antibiotics (green line). On the basis of annual 
comparisons by means of the Mann–Whitney nonparametric test, a single 
asterisk indicates P = 0.07, and double asterisks indicate P = 0.002.
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15 exacerbations. Using data from the remaining 
patients, we plotted the percentage of nonmucoid 
versus mucoid P. aeruginosa according to the men-
strual-cycle phase when the exacerbation occurred. 
Mucoid P. aeruginosa accounted for 63.0% of the 
isolates in the follicular phase (high estradiol), as 
compared with 16.7% nonmucoid isolates. In the 
luteal phase (low estradiol), we isolated no mu-
coid P. aeruginosa, whereas 72.2% of the samples 
contained nonmucoid P. aeruginosa (Fig. 4A).
To further assess this relationship, we record-
ed changes in the proportion of mucoid and non-
mucoid P. aeruginosa, using serially diluted sputum 
samples obtained from six women with cystic fi-
brosis and stable menstrual cycles who were 
known to be colonized by both organisms. In 
these women, we observed an increase in mucoid 
isolation at times of high estradiol levels (Fig. 4B, 
and Fig. S9 in the Supplementary Appendix). This 
finding explains the lack of mucoid isolation 
during the luteal phase that was observed in our 
undiluted sputum samples (Fig. 4A). We also 
assessed changes in mucoid and nonmucoid pro-
portions in sputum samples during stable and 
exacerbation states. During exacerbations, non-
mucoid counts tripled, as compared with the 
stable state, whereas mucoid counts increased 
by a factor of more than 50. These changes oc-
curred in the presence of an increased serum 
estradiol level (Fig. S10 in the Supplementary 
Appendix).
Mucoid Conversion and Pregnancy
In further support of the hypothesis that estradiol 
and estriol are important factors in mucoid con-
version of P. aeruginosa in vivo, we also assessed the 
physiologically estriol-dominant state of preg-
nancy. We assessed patients who were colonized 
with nonmucoid P. aeruginosa before pregnancy for 
the time to mucoid conversion after pregnancy. 
During a 15-year period (1996–2010), this occurred 
in 4 of 7 pregnancies (57.1%) within 12 months 
after delivery and in 5 of 7 pregnancies (71.4%) 
within 24 months (in a total of 11 pregnancies) 
(Table S10 in the Supplementary Appendix). Data 
from the Irish registry from 2001 through 2010 
(involving 14 pregnancies) showed that mucoid 
conversion occurred in 5 of 7 pregnancies (71.4%) 
within 12 months after delivery and in 6 of 7 
(85.7%) within 24 months (Table S10 in the Sup-
plementary Appendix).
Discussion
It has been observed that women with cystic fi-
brosis acquire P. aeruginosa in advance of men and 
convert to mucoid strains prematurely.3,5,10,11 In 
our study, we found that estradiol promoted mu-
coid conversion of P. aeruginosa, increased algi-
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Figure 4. Mucoid and Nonmucoid Pseudomonas 
Species and Estradiol Levels in Women with Cystic  
Fibrosis.
Panel A shows the percentage of patients who were 
colonized with mucoid versus nonmucoid pseudomonas 
species during exacerbations throughout the menstrual 
cycle. Pseudomonas species were cultured from undi-
luted sputum samples obtained from women with cystic 
fibrosis who were undergoing exacerbations (54 in the 
follicular phase and 18 in the luteal phase) and identi-
fied as either mucoid or nonmucoid. Panel B shows 
the in vivo variability of the P. aeruginosa phenotype in 
relation to levels of serum estradiol (E2) during the 
course of the menstrual cycle in 6 women with stable 
cystic fibrosis and regular menses, according to whether 
the sample was mucoid (M) or nonmucoid (NM).
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nate production in P. aeruginosa, and (owing to 
impaired catalase activity and increased levels of 
hydrogen peroxide) selected for mutations in mucA, 
a negative regulator of alginate synthesis. In vivo 
estradiol levels correlated with infective exacer-
bations among menstruating women with cystic 
fibrosis, and mucoid P. aeruginosa was selectively 
grown during periods with high levels of circu-
lating estradiol.
Microbial endocrinology suggests that estradiol 
may directly affect the development of prokary-
otes.30,31 Proteinaceous estrogen-binding receptors 
have been reported in P. aeruginosa and Escherichia 
coli.32-34 P. aeruginosa can actively metabolize steroid 
hormones35 and use estradiol as a carbon source.36 
In our study, estriol, although less potently es-
trogenic than estradiol, was a stronger inducer 
of alginate. Airway epithelial cells can metabolize 
estradiol to estriol, which was also detected in 
samples of bronchoalveolar-lavage fluid obtained 
from women with cystic fibrosis. Other airway 
organisms and inflammatory cells may contribute 
to this pool of estriol. Although estriol was de-
tected in samples of bronchoalveolar-lavage fluid 
obtained from men with cystic fibrosis, the levels 
were significantly lower than those obtained from 
women.
Nonmucoid PA01 can produce alginate18 and is 
a suitable model for the study of alginate produc-
tion.24,28 Estradiol significantly increased alginate 
production related to early mucoid morphology on 
blue agar after 4 weeks.37 In translating our find-
ings to the airways of women with cystic fibrosis, 
we found that clinical isolates of P. aeruginosa pro-
duced higher baseline and estradiol-induced algi-
nate levels than did PA01. Thus, long-term expo-
sure of P. aeruginosa to estradiol after menarche 
from repeated menstrual cycling places women 
with cystic fibrosis at increased risk for mucoid 
conversion. The high rates of mucoid conversion 
among women in the Irish registry and after preg-
nancy support this finding.
We also identified a mutation in mucA that 
leads to mucoidy. Neutrophils in the lungs of pa-
tients with cystic fibrosis release hydrogen per-
oxide, a DNA-damaging agent that can result in 
mutations in mucA.38 Estradiol can independent-
ly generate hydrogen peroxide and other free 
radicals.39,40 Consequently, we assessed the ef-
fect of estradiol on hydrogen peroxide genera-
tion by P. aeruginosa. We found elevated hydro-
gen peroxide levels after short-term exposure of 
P. aeruginosa to estradiol, and the activity of cata-
lase, the enzyme that detoxifies hydrogen per-
oxide, was inhibited.
Among patients with cystic fibrosis, mucoid 
P. aeruginosa is observed at higher frequencies in 
women than in men, and female sex is recognized 
as a risk factor for early conversion.10,11 The me-
dian age of chronic infection with mucoid P. aeru-
ginosa has been reported to be 1.7 years earlier in 
women, which accelerates the rate of decline in 
pulmonary function.3 The age-specific prevalence 
of mucoid P. aeruginosa in patients with cystic fi-
brosis markedly increases after puberty.1 In the 
United States, a case–control analysis of the Cys-
tic Fibrosis Foundation registry confirmed that an 
earlier age of P. aeruginosa infection was associated 
with increased odds of severe lung disease, a rela-
tionship that was found to be stronger in women.41 
Although no significant differences were detected 
in the prevalence of chronic P. aeruginosa infection 
in a Scandinavian population, the incidence of new 
infection was higher in women.5 An assessment of 
the Irish registry showed that rates of P. aeruginosa 
colonization and mucoid conversion were higher 
in women than in men, along with earlier ages of 
acquisition and mucoid conversion.
To investigate the link between estradiol, infec-
tive exacerbations, and mucoidy in women with 
cystic fibrosis, we conducted a clinical study relat-
ing infective exacerbations to the day in the men-
strual cycle when the exacerbation occurred. A 
significant relationship between exacerbations and 
estradiol levels was evident, with the majority of 
exacerbations occurring during the follicular 
phase, a stage with the highest estradiol level.
At our institution, women with cystic fibrosis 
who were receiving oral contraceptives had lower 
rates of exacerbation. Using registry data, we 
found that women receiving oral contraceptives 
required a lower number of antibiotic courses than 
did women not receiving oral contraceptives and 
that individual women required less use of anti-
biotics during the time they were receiving oral 
contraceptives than during the time they were not 
receiving oral contraceptives. Although oral contra-
ceptives may be protective against exacerbations, 
a double-blind, placebo-controlled study of the use 
of oral contraceptives in women with cystic fibro-
sis would be necessary to provide proof. Future 
work should also account for the various subtypes 
of oral contraceptives, colonization with other 
organisms, and their antibiotic resistances.
During our clinical study, although mucoid 
bacteria were predominantly isolated during high-
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estradiol phases of the menstrual cycle, as com-
pared with nonmucoid bacteria in low-estradiol 
phases, proportional differences between the 
P. aeruginosa phenotypes were evident, a finding 
that illustrates a selective isolation of mucoid 
P. aeruginosa during periods of high levels of circu-
lating estradiol. Although much has been learned 
about the role of estradiol within the airways of 
patients with cystic fibrosis, further work is neces-
sary, particularly in the assessment of the use of 
oral contraceptives and its potential effect on exac-
erbations and the microbial endocrine effects of 
estradiol on P. aeruginosa.
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